207 related articles for article (PubMed ID: 26775883)
21. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
Schindler J; Gajavelli S; Ravandi F; Shen Y; Parekh S; Braunchweig I; Barta S; Ghetie V; Vitetta E; Verma A
Br J Haematol; 2011 Aug; 154(4):471-6. PubMed ID: 21732928
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
[TBL] [Abstract][Full Text] [Related]
23. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
24. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
Krop IE; Modi S; LoRusso PM; Pegram M; Guardino E; Althaus B; Lu D; Strasak A; Elias A
Breast Cancer Res; 2016 Mar; 18(1):34. PubMed ID: 26979312
[TBL] [Abstract][Full Text] [Related]
25. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
[TBL] [Abstract][Full Text] [Related]
26. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
Jabbour EJ; DeAngelo DJ; Stelljes M; Stock W; Liedtke M; Gökbuget N; O'Brien S; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS; Kantarjian HM
Cancer; 2018 Apr; 124(8):1722-1732. PubMed ID: 29381191
[TBL] [Abstract][Full Text] [Related]
28. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
[TBL] [Abstract][Full Text] [Related]
29. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
[TBL] [Abstract][Full Text] [Related]
30. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
Bachanova V; Frankel AE; Cao Q; Lewis D; Grzywacz B; Verneris MR; Ustun C; Lazaryan A; McClune B; Warlick ED; Kantarjian H; Weisdorf DJ; Miller JS; Vallera DA
Clin Cancer Res; 2015 Mar; 21(6):1267-72. PubMed ID: 25770294
[TBL] [Abstract][Full Text] [Related]
33. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
[TBL] [Abstract][Full Text] [Related]
34. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
[TBL] [Abstract][Full Text] [Related]
35. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
36. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
Younes A; Sureda A; Ben-Yehuda D; Zinzani PL; Ong TC; Prince HM; Harrison SJ; Kirschbaum M; Johnston P; Gallagher J; Le Corre C; Shen A; Engert A
J Clin Oncol; 2012 Jun; 30(18):2197-203. PubMed ID: 22547596
[TBL] [Abstract][Full Text] [Related]
37. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Goldberg AD; Atallah E; Rizzieri D; Walter RB; Chung KY; Spira A; Stock W; Tallman MS; Cruz HG; Boni J; Havenith KEG; Chao G; Feingold JM; Wuerthner J; Solh M
Leuk Res; 2020 Aug; 95():106385. PubMed ID: 32521310
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
Jabbour E; O'Brien S; Huang X; Thomas D; Rytting M; Sasaki K; Cortes J; Garcia-Manero G; Kadia T; Ravandi F; Pierce S; Kantarjian H
Am J Hematol; 2015 Mar; 90(3):193-6. PubMed ID: 25407953
[TBL] [Abstract][Full Text] [Related]
39. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
Kollmannsberger C; Britten CD; Olszanski AJ; Walker JA; Zang W; Willard MD; Radtke DB; Farrington DL; Bell-McGuinn KM; Patnaik A
Invest New Drugs; 2021 Dec; 39(6):1613-1623. PubMed ID: 34264412
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Wayne AS; Shah NN; Bhojwani D; Silverman LB; Whitlock JA; Stetler-Stevenson M; Sun W; Liang M; Yang J; Kreitman RJ; Lanasa MC; Pastan I
Blood; 2017 Oct; 130(14):1620-1627. PubMed ID: 28983018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
